Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22253433 | 0.83 | GRIN1 (0.36) | — | |
| SCHEMBL22255144 | 0.82 | AAK1 (0.33) | — | |
| SCHEMBL18812112 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL22516414 | 0.69 | — | — | |
| SCHEMBL830187 | 0.69 | CYP1A2 (0.37) | — | |
| Ammonia Solution, Strong SCHEMBL28652832 | 0.68 | CYP1A2 (0.36) | — | |
| SCHEMBL22242092 | 0.66 | GRIN1 (0.32) | — | |
| Ammonia Solution, Strong SCHEMBL11451734 | 0.66 | CYP1A2 (0.35) | — | |
| SCHEMBL23015683 | 0.65 | TRPV3 (0.38) | — | |
| SCHEMBL21087455 | 0.65 | DHFR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | LATS1 2295/4885LATS2 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.